Q
QuantAbundance

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,744 signal articles · 84 in last 24h · 156,553 total before filter · latest 1h ago
84last 24h
845last 7d
150● bullish (7d)
87● bearish (7d)
214publishers
AllMacro188Earnings122M&A113Regulatory20Product19Analyst22
✕ clear all filterssentiment: bearishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
AMD falls after Musk says SpaceX will exclusively use Nvidia AI chips
InvestorsHub53d agobearish
AMD falls after Musk says SpaceX will exclusively use Nvidia AI chips

Advanced Micro Devices (NASDAQ:AMD) shares dropped more than 6% in early trading on Wednesday after Elon Musk revealed that SpaceX plans to source its artificial intelligence processors exclusively from Nvidia, overshadowing AMD’s stronger-than-expected quarterly earnings. The announcement weighed heavily on investor sentiment despite another quarter of record revenue and upbeat guidance from the semiconductor company.

AZN rebounds after report dismisses AstraZeneca-Bristol Myers merger speculation
InvestorsHub54d agobearish
AZN rebounds after report dismisses AstraZeneca-Bristol Myers merger speculation

AstraZeneca (NASDAQ:AZN) shares climbed around 6% on Wednesday after Reuters reported that there are “no discussions” between the company and Bristol Myers Squibb (NYSE:BMY) regarding a potential merger, contradicting recent speculation that had unsettled investors. The report eased concerns surrounding a deal that, if completed, would have created a pharmaceutical group valued at close to $400 billion.

Bloomberg54d agobearish
CVS Falls After Preliminary 2027 Guidance Disappoints

(Bloomberg) -- CVS Health Corp. shares fell after the company gave preliminary 2027 profit guidance that disappointed investors and warned of challenges in its pharmacy benefit manager next year, overshadowing a better-than-expected second quarter report.Most Read from BloombergTrump Says Iran Talks Going Well as Hopes Rise for Hormuz DealSpaceX’s AI Splurge Puts Damper on Debut Earnings After IPOChina’s AI Blitz Creates ‘Death Zone’ for Rival US Model MakersTaco Bell Met With Michigan on Parasi

Roblox Sentiment Is Mixed Post-Crash: Buy, Sell, or Hold Now?
24/7 Wall St.54d agobearish
Roblox Sentiment Is Mixed Post-Crash: Buy, Sell, or Hold Now?

Roblox stock shed more than 70% of its value in a year, yet Wall Street analysts and company insiders are moving in the opposite direction from the selloff. Here is what the conflicting signals actually mean for investors sitting on the sidelines.

Is ServiceNow (NOW) a Mispriced AI Winner After the Software Sell-Off?
Insider Monkey54d agobearish
Is ServiceNow (NOW) a Mispriced AI Winner After the Software Sell-Off?

Emerald Wealth Partners, an independent asset and wealth management firm based in Zurich, released its Q2 2026 investor letter for the “Focused Equity Strategy.” A copy of the letter can be downloaded here. The Strategy reported a 0.8% gross return for the second quarter of 2026. Equity markets rallied after the first quarter’s Iran shock faded and […]

SolarEdge (NASDAQ:SEDG) Posts Better-Than-Expected Sales In Q2 CY2026 But Stock Drops
StockStory54d agobearish
SolarEdge (NASDAQ:SEDG) Posts Better-Than-Expected Sales In Q2 CY2026 But Stock Drops

Solar power systems company SolarEdge (NASDAQ:SEDG) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 19.6% year on year to $346.2 million. On the other hand, next quarter’s revenue guidance of $325 million was less impressive, coming in 12.6% below analysts’ estimates. Its non-GAAP profit of $0.05 per share was significantly above analysts’ consensus estimates.

Novo Nordisk shares fall despite improved outlook as Wegovy sales disappoint
InvestorsHub54d agobearish
Novo Nordisk shares fall despite improved outlook as Wegovy sales disappoint

Novo Nordisk (NYSE:NVO) raised its full-year guidance after reporting continued demand for its weight-loss treatments, but weaker-than-expected sales of its oral Wegovy medication and disappointing clinical trial results for a next-generation obesity therapy weighed heavily on investor sentiment. The company’s shares dropped 6% during US trading on Tuesday, while its Copenhagen-listed stock declined 4.

Disney (NYSE:DIS) Misses Q2 CY2026 Revenue Estimates
StockStory54d agobearish
Disney (NYSE:DIS) Misses Q2 CY2026 Revenue Estimates

Global entertainment and media company Disney (NYSE:DIS) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.8% year on year to $25.25 billion. Its non-GAAP profit of $2.06 per share was 11.1% above analysts’ consensus estimates.